Glendale, AZ5 Active Studies

Heart Attack Clinical Trials in Glendale, AZ

Find 5 actively recruiting heart attack clinical trials in Glendale, AZ. Connect with local research sites and explore new treatment options.

5
Active Trials
4
Sponsors
2,590
Enrolling

Recruiting Heart Attack Studies in Glendale

RecruitingGlendale, AZNCT05843643

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult...

1,000 participants
AbbVie
View Study Details
RecruitingGlendale, AZNCT04961567

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active...

540 participants
Biogen
View Study Details
RecruitingGlendale, AZNCT06617325

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of mo...

450 participants
UCB Biopharma SRL
View Study Details
RecruitingGlendale, AZNCT06079879

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate re...

300 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingGlendale, AZNCT06456346

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreduct...

300 participants
Merck Sharp & Dohme LLC
View Study Details

About Heart Attack Clinical Trials in Glendale

A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.

There are currently 5 heart attack clinical trials recruiting participants in Glendale, AZ. These studies are seeking a combined 2,590 participants. Research is being sponsored by AbbVie, Biogen, UCB Biopharma SRL and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Heart Attack Clinical Trials in Glendale — FAQ

Are there heart attack clinical trials in Glendale?

Yes, there are 5 heart attack clinical trials currently recruiting in Glendale, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Glendale?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Glendale research site will contact you about next steps.

Are clinical trials in Glendale free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Glendale studies also compensate for your time and travel.

What heart attack treatments are being tested?

The 5 active trials in Glendale are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.

Data updated March 2, 2026 from ClinicalTrials.gov